The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention provides compositions and methods for inhibiting PTPN22 for restoring human central B-cell tolerance or for treating or preventing an autoimmune disease or disorder.

The present invention provides compositions and methods for inhibiting PTPN22 for restoring human central B-cell tolerance or for treating or preventing an autoimmune disease or disorder.

Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical composition comprising compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases.

Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical composition comprising compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases.

Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical composition comprising compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases.

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.